Core Insights - Blarcamesine, a drug candidate from Anavex, shows performance comparable to Aricept in treating Alzheimer's disease, indicating limited efficacy in addressing the disease's progression [1] - The underlying causes of Alzheimer's disease are linked to oxidation and nitration, with current treatments primarily targeting symptoms rather than the root causes [1] - Natural products like panax ginseng and essential oils may offer potential benefits by inhibiting oxidative stress and reversing some damage, suggesting alternative treatment avenues [1] - Anavex and Cyclo Therapeutics are highlighted as companies with promising drug candidates in the Alzheimer's space, making them recommended investment opportunities [1] Company Analysis - Anavex's long-term open label trial results are being reassessed to understand the mechanisms of action of its drug candidate, blarcamesine [1] - The company is positioned within a niche market focused on innovative treatments for Alzheimer's, which is characterized by a need for more effective solutions [1] - Cyclo Therapeutics is also mentioned as a company with potential in developing treatments that may stabilize Alzheimer's disease [1]
The Unusual Effects Of Anavex's Blarcamesine On Alzheimer's Disease (Upgrade)